UFPT · Ufp Technologies Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $67.3M | six-month period ended June 30, 2026 | — |
|
|
|||
| Adjusted net income non-GAAP | $42.1M | six-month period ended June 30, 2026 | — |
|
|
|||
| Adjusted net income per diluted share outstanding (Non-GAAP) non-GAAP | $5.39 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted operating income non-GAAP | $56.5M | six-month period ended June 30, 2026 | — |
|
|
|||
| Adjusted SG&A (Non-GAAP) non-GAAP | 38.82M | Six Months Ended June 30, 2026 | — |
| Adjusted SG&A as a % of sales non-GAAP | 11.8% | Six Months Ended June 30, 2026 | — |
|
|
|||
| EBITDA (Non-GAAP) non-GAAP | 61.35M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Organic sales non-GAAP | 169.9M | Three Months Ended June 30, 2026 | — |
| Organic sales growth non-GAAP | 6.8% | six-month period ended June 30, 2026 | — |
|
|
|||
| Adjusted gross margin non-GAAP | 28.8% | three months ended March 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UFPT
this stock
Ufp Technologies Inc
|
$2.32B | +35.1% | +19.5% | 32.3 | 13.9% |
|
ABT
Abbott Laboratories
|
$195.90B | -10.2% | +5.7% | 31.5 | 1.2% |
|
SYK
Stryker Corp
|
$127.12B | -5.9% | +11.2% | 34.3 | 1.8% |
|
MDT
Medtronic plc
|
$116.78B | -5.0% | +8.4% | 24.5 | 1.1% |
|
BSX
Boston Scientific Corp
|
$67.88B | -50.9% | +12.5% | 19.0 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UFPT | -2.9% | +17.8% | +39.6% | +17.8% | +35.1% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -3.4% | +14.8% | +26.1% | +14.8% | +22.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.